Clinical Trial of Atezolizumab With Paclitaxel Trastuzumab and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

  • End date
    Dec 31, 2023
  • participants needed
  • sponsor
    Fox Chase Cancer Center
Updated on 31 January 2021
ct scan
ejection fraction
measurable disease
breast cancer
gilbert's syndrome
tumor cells
bone metastases
gene amplification
her2 gene amplification
her-2 positive breast cancer


This is a single arm, Phase IIA clinical trial assessing the safety and efficacy of atezolizumab in combination with paclitaxel, trastuzumab, and pertuzumab in 50 patients with locally advanced, unresectable, or metastatic HER2-overexpressing breast cancer. Due to concerns that corticosteroids may have a negative effect on tumor immunity expected with addition of atezolizumab to the standard of care regimen, patients will receive premedication with dexamethasone only for weeks 1 and 2 of the weekly paclitaxel, and then corticosteroid premedication will be discontinued subsequently.

Patients must have pathologically confirmed HER2-overexpressing breast cancer that is locally recurrent, unresectable, or metastatic, with measurable disease as defined by RECIST v1.1. Tumor measurements and bone scans will be performed every 9 weeks while patients are on study.

Condition HER2 Positive Breast Cancer, her2/neu-positive breast cancer, her2-positive breast cancer
Treatment Paclitaxel, Trastuzumab, Pertuzumab, Atezolizumab
Clinical Study IdentifierNCT03125928
SponsorFox Chase Cancer Center
Last Modified on31 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Are you female?
Do you have HER2 Positive Breast Cancer?
Do you have any of these conditions: HER2 Positive Breast Cancer or her2/neu-positive breast cancer or her2-positive breast cancer?
Women diagnosed with pathologically confirmed HER2-overexpressing breast cancer, that is locally recurrent, unresectable or metastatic (negative or positive for ER/PR, and positive for HER2)
HER2 status confirmed positive by means of immunohistochemistry (IHC) or in situ hybridization (ISH) according to ASCO/CAP 2013 guidelines. It is considered positive if scored as 3+ by an IHC method defined as uniform membrane staining for HER2 in 10% or more of tumor cells or demonstrate HER2 gene amplification by an ISH method (single probe, average HER2 copy number 6.0 signals/cell; dual probe HER2/CEP17 ratio 2.0 with an average HER2 copy number 4.0 signals/cell; dual probe HER2/chromosome enumeration probe (CEP)17 ratio 2.0 with an average HER2 copy number <4.0 signals/cell; HER2/CEP17 ratio <2.0 with an average HER2 copy number 6.0 signals/cell)
Have measurable clinical disease: Measurable disease, defined as at least 1 measurable lesion on a CT scan as defined by RECIST (version v1.1)
Age > 18 years
ECOG performance status 0,1or 2
Adequate organ function (defined by the following parameters): Absolute neutrophil count (ANC) 1.5 x 109/L. Hemoglobin 10 g/dL.Platelets 100 x 109/L. Serum bilirubin 1.5 x upper normal limit (UNL), except patients with Gilbert's syndrome. Serum alanine aminotransferase (ALT) 2 x UNL or 5.0 x UNL in case of liver metastases. Serum aspartate aminotransferase (AST) 2 x UNL or 5.0 x UNL in case of liver metastases. Serum creatinine < 140 mol/L (< 1.6 mg/dL) or 1.5x the upper limit of normal, whichever is less. Serum alkaline phosphatase (ALP) UNL or 2.5 x ULN in case of liver and bone metastases
Left ventricular ejection fraction of 50% or more at baseline (by echocardiography or multiple-gated acquisition scanning)
Patients may have received one prior hormonal treatment for metastatic disease
Patients may have received adjuvant or neoadjuvant chemotherapy with or without trastuzumab and pertuzumab with an interval greater than than 12 months since completion of adjuvant/neoadjuvant treatment
Ability to understand and willingness to sign a written informed consent and HIPAA consent document
Female participants of childbearing age must be willing to use contraception methods, or abstain from sexual activity throughout the course of the study and for 7 months after the last dose of atezolizumab
Have provided tissue from a newly obtained biopsy obtained from a focus of metastatic disease, and be willing to consider repeat biopsy post-treatment after at least 4 cycles of treatment (an archival tissue sample may be substituted if new biopsy cannot be obtained and by discretion of Sponsor Investigator)

Exclusion Criteria

Patients participating in another trial of an investigational agent within 4 weeks of the 1st dose of the study
Patients with tumors that cannot be measured or clinically followed
Patients who had received therapy for metastatic breast cancer (other than that described above)
Patients with active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 4 weeks prior to trial treatment
Patients with any baseline grade 2 neuropathy
Patients with known prior hypersensitivity reaction to any of the study drugs
Active autoimmune disease that is requiring systemic treatment within the past 3 months or documented history of clinically active autoimmune disease that requires systemic corticosteroids or immunosuppressive therapy
Diagnosis of immunosuppression or receiving steroid therapy or other immunosuppressive therapy within 4 weeks of the study
Have evidence of interstitial lung disease or active, non-infectious pneumonitis
Patients with human immunodeficiency virus (HIV1/2). An HIV test must be performed to confirm status prior to enrollment
Patients who are carriers of hepatitis virus B and C. Hepatitis B and C testing must be performed to confirm status prior to enrollment
Prior therapy with an anti-programmed cell death 1 (PD-1), anti-programmed cell death 1 ligand (PDL-1), anti-PD-L2, anti-CD137 antibody, or anti-cytotoxic T-lymphocyte -associated antigen-4 (CTLA-4) antibody
Pregnant, breastfeeding, or expecting to conceive within the projected time of the trial, starting with the pre-screening or screening visit and through 7 months after the last dose of trial treatment
Active infection requiring systemic therapy
Active substance abuse or psychiatric disorders
The use of a RANKL inhibitor (denosumab) must be discontinued during the study. Bisphosphonate therapy is permitted
The following treatments must be discontinued: Herbal Medications. Immunomodulatory agents, including but not limited to interferons or IL-2. Immunosuppressive medications, including but not limited to cyclophosphamide, azathioprine, methotrexate, and thalidomide. Systemic corticosteroids. Anti-TNF- agents
Any live, attenuated vaccine within 28 days prior to the first day of treatment or during study treatment, or unwillingness to avoid live, attenuated vaccines within 90 days following the last dose of atezolizumab
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note